Neobractatin and Trametinib Synergistically Induce Apoptosis and Gasdermin E-Dependent Pyroptosis in Pancreatic Cancer Cells

Abstract

Mutations in mitogen-activated protein kinase kinase (MEK) are prevalent in pancreatic ductal adenocarcinoma (PDAC), but many MEK inhibitors inadvertently activate protein kinase B (AKT). We propose a promising PDAC treatment strategy by combining the MEK inhibitor trametinib with neobractatin (NBT), a natural compound from Garcinia bracteata. Our results demonstrated that this combination significantly impeded cell growth by inducing gasdermin E (GSDME)-mediated pyroptosis and apoptosis. GSDME, overexpressed in PDAC tissues and correlated with histological differentiation, underscores the role of pyroptosis in PDAC. RNA-seq results indicated that the phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) pathway was the primary target of the combination treatment. Mechanistic studies revealed the combination effectively reduced both total and phosphorylated AKT levels, thereby inhibiting protein kinase B/IκB kinase (AKT/IKK) and protein kinase B/mammalian target of rapamycin (AKT/mTOR) signaling pathways. Additionally, the combination disrupted mTOR complex 2 (mTORC2), preventing the trametinib-induced AKT activation. MicroRNA sequencing analysis indicated that the combination reduced AKT levels by upregulated miR-149-5p. Further research demonstrated that the combination increased intracellular reactive oxygen species (ROS), while N-acetylcysteine (NAC, a ROS scavenger) reversed the cell growth inhibition and AKT suppression. In vivo, the combination significantly inhibited tumor growth by inducing pyroptosis and apoptosis, outperforming gemcitabine. Our findings provide novel insights into the potential of combining NBT and trametinib to induce pyroptosis and apoptosis through the ROS/AKT/GSDME axis, offering a theoretical basis for future PDAC treatment.

Keywords

AKT / gasdermin E / pancreatic ductal adenocarcinoma / pyroptosis / ROS

References

[1] R. L. Siegel, K. D. Miller, N. S. Wagle, and A. Jemal, “Cancer Statistics, 2023,” CA: A Cancer Journal for Clinicians 73, no. 1 (2023): 17-48.

[2] R. Zheng, S. Zhang, H. Zeng, et al., “Cancer Incidence and Mortality in China, 2016,” Journal of the National Cancer Center 2, no. 1 (2022): 1-9.

[3] H. C. Kung and J. Yu, “Targeted Therapy for Pancreatic Ductal Adenocarcinoma: Mechanisms and Clinical Study,” MedComm 4, no. 2 (2023): e216.

[4] American Cancer Society. Cancer Facts & Figures 2020. American Cancer; 2020.

[5] L. D. Wood, M. I. Canto, E. M. Jaffee, and D. M. Simeone, “Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment,” Gastroenterology 163, no. 2 (2022): 386-402.e1.

[6] M. Dankner, A. A. N. Rose, S. Rajkumar, P. M. Siegel, and I. R. Watson, “Classifying BRAF Alterations in Cancer: New Rational Therapeutic Strategies for Actionable Mutations,” Oncogene 37, no. 24 (2018): 3183-3199.

[7] J. Timar and K. Kashofer, “Molecular Epidemiology and Diagnostics of KRAS Mutations in human Cancer,” Cancer and Metastasis Reviews 39, no. 4 (2020): 1029-1038.

[8] Y. J. Gao, A. Maria, N. Na, et al., “V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer,” Cancer Discovery 9, no. 9 (2019): 1182-1191.

[9] A. M. Menzies and G. V. Long, “Dabrafenib and trametinib, Alone and in Combination for BRAF-mutant Metastatic Melanoma,” Clinical Cancer Research 20, no. 8 (2014): 2035-2043.

[10] L. Odogwu, L. Mathieu, G. Blumenthal, et al., “FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring BRAF V600E Mutations,” The Oncologist 23, no. 6 (2018): 740-745.

[11] M. C. Mendoza, E. E. Er, and J. Blenis, “The Ras-ERK and PI3K-mTOR Pathways: Cross-talk and Compensation,” Trends in Biochemical Sciences 36, no. 6 (2011): 320-328.

[12] K. L. Bryant, C. A. Stalnecker, D. Zeitouni, et al., “Combination of ERK and Autophagy Inhibition as a Treatment Approach for Pancreatic Cancer,” Nature Medicine 26, no. 6 (2020): 982-982.

[13] J. Weisner, I. Landel, C. Reintjes, et al., “Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination With Trametinib in KRAS-Mutant Pancreatic and Colorectal Cancer,” Cancer Research 79, no. 9 (2019): 2367-2378.

[14] C. Y. Sun, Y. Z. Li, D. Cao, Y. F. Zhou, M. Y. Zhang, and H. Y. Wang, “Rapamycin and Trametinib: A Rational Combination for Treatment of NSCLC,” International Journal of Biological Sciences 17, no. 12 (2021): 3211-3223.

[15] C. B. Xavier, K. R. Marchetti, T. B. Castria, D. L. F. Jardim, and G. S. Fernandes, “Trametinib and Hydroxychloroquine (HCQ) Combination Treatment in KRAS-Mutated Advanced Pancreatic Adenocarcinoma: Detailed Description of Two Cases,” Journal of Gastrointestinal Cancer 52, no. 1 (2021): 374-380.

[16] J. M. Mehnert, T. C. Mitchell, A. C. Huang, et al., “BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma,” Clinical Cancer Research 28, no. 6 (2022): 1098-1106.

[17] A. Rejhova, A. Opattova, A. Cumova, D. Sliva, and P. Vodicka, “Natural Compounds and Combination Therapy in Colorectal Cancer Treatment,” European Journal of Medicinal Chemistry 144 (2018): 582-594.

[18] J. Zhang, Z. Zheng, M. Wu, et al., “The Natural Compound Neobractatin Inhibits Tumor Metastasis by Upregulating the RNA-binding-protein MBNL2,” Cell Death & Disease 10, no. 8 (2019): 554.

[19] Z. Zheng, J. Tan, J. Zhang, et al., “The Natural Compound Neobractatin Inhibits Cell Proliferation Mainly by Regulating the RNA Binding Protein CELF6,” Food & Function 13, no. 4 (2022): 1741-1750.

[20] Z. Zheng, M. Wu, J. Zhang, et al., “The Natural Compound Neobractatin Induces Cell Cycle Arrest by Regulating E2F1 and Gadd45alpha,” Frontiers in Oncology 9 (2019): 654.

[21] J. Q. Tan, Z. Li, G. Chen, et al., “The Natural Compound From Garcinia bracteata Mainly Induces GSDME-mediated Pyroptosis in Esophageal Cancer Cells,” Phytomedicine 102 (2022): 154142.

[22] Y. P. Wang, W. Q. Gao, X. Y. Shi, et al., “Chemotherapy Drugs Induce Pyroptosis Through Caspase-3 Cleavage of a Gasdermin,” Nature 547, no. 7661 (2017): 99-103.

[23] Z. Zhang, S. Zhao, H. Yang, et al., “Prognostic and Immunological Role of Gasdermin E in Pan-Cancer Analysis,” Frontiers in Oncology 11 (2021): 706266.

[24] X. Xia, X. Wang, Z. Cheng, et al., “The Role of Pyroptosis in Cancer: Pro-cancer or Pro-“Host”?,” Cell Death & Disease 10, no. 9 (2019): 650.

[25] L. Li, S. Wang, and W. Zhou, “Balance Cell Apoptosis and Pyroptosis of Caspase-3-Activating Chemotherapy for Better Antitumor Therapy,” Cancers (Basel) 15, no. 1 (2022): 26.

[26] M. Shariati and F. Meric-Bernstam, “Targeting AKT for Cancer Therapy,” Expert Opinion on Investigational Drugs 28, no. 11 (2019): 977-988.

[27] C. A. Hoeffer and E. Klann, “mTOR Signaling: At the Crossroads of Plasticity, Memory and Disease,” Trends in Neuroscience (Tins) 33, no. 2 (2010): 67-75.

[28] W. S. Brown, P. C. McDonald, O. Nemirovsky, et al., “Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer,” Cell Reports Medicine 1, no. 8 (2020): 100131.

[29] X. Zhang, P. Zhang, L. An, et al., “Miltirone Induces Cell Death in Hepatocellular Carcinoma Cell Through GSDME-dependent Pyroptosis,” Acta Pharmaceutica Sinica B 10, no. 8 (2020): 1397-1413.

[30] S. Li, M. Yue, H. Xu, et al., “Chemotherapeutic Drugs-induced Pyroptosis Mediated by gasdermin E Promotes the Progression and Chemoresistance of Pancreatic Cancer,” Cancer Letters 564 (2023): 216206.

[31] G. Li, P. Li, Q. Jiang, et al., “Discovery of a Pyridophenoselenazinium-based Photosensitizer With High Photodynamic Efficacy Against Breast Cancer Cells,” Acta Materia Medica 2, no. 1 (2023): 96-105.

[32] X. Zhang, S. Wang, H. Wang, et al., “Circular RNA circNRIP1 Acts as a microRNA-149-5p Sponge to Promote Gastric Cancer Progression via the AKT1/mTOR Pathway,” Molecular Cancer 18, no. 1 (2019): 20.

[33] X. Jin, Y. Ma, D. Liu, and Y. Huang, “Role of Pyroptosis in the Pathogenesis and Treatment of Diseases,” MedComm 4, no. 3 (2023): e249.

[34] W. Xie, X. Li, C. Yang, et al., “The Pyroptosis-Related Gene Prognostic Index Associated With Tumor Immune Infiltration for Pancreatic Cancer,” International Journal of Molecular Sciences 23, no. 11 (2022): 6178.

[35] T. Yu, H. Tan, C. Liu, et al., “Integratively Genomic Analysis Reveals the Prognostic and Immunological Characteristics of Pyroptosis and Ferroptosis in Pancreatic Cancer for Precision Immunotherapy,” Frontiers in Cell and Developmental Biology 10 (2022): 826879.

[36] W. Yao, P. Yue, G. Zhang, T. K. Owonikoko, F. R. Khuri, and S. Y. Sun, “Enhancing Therapeutic Efficacy of the MEK Inhibitor, MEK162, by Blocking Autophagy or Inhibiting PI3K/Akt Signaling in human Lung Cancer Cells,” Cancer Letters 364, no. 1 (2015): 70-78.

[37] J. Xu, X. Yu, T. C. Martin, et al., “AKT Degradation Selectively Inhibits the Growth of PI3K/PTEN Pathway-Mutant Cancers With Wild-Type KRAS and BRAF by Destabilizing Aurora Kinase B,” Cancer Discovery 11, no. 12 (2021): 3064-3089.

[38] H. Shigaki, Y. Baba, M. Watanabe, et al., “KRAS and BRAF Mutations in 203 Esophageal Squamous Cell Carcinomas: Pyrosequencing Technology and Literature Review,” Annals of Surgical Oncology 20, Suppl no. 3 (2013): S485-S491.

[39] X. Ding, X. L. Zhu, D. H. Xu, et al., “NPM Promotes Hepatotoxin-induced Fibrosis by Inhibiting ROS-induced Apoptosis of Hepatic Stellate Cells and Upregulating lncMIAT-induced TGF-beta2,” Cell Death & Disease 14, no. 8 (2023): 575.

[40] Y. Zhang, X. Guo, L. Xiong, et al., “Comprehensive Analysis of microRNA-regulated Protein Interaction Network Reveals the Tumor Suppressive Role of microRNA-149 in human Hepatocellular Carcinoma via Targeting AKT-mTOR Pathway,” Molecular Cancer 13 (2014): 253.

[41] A. Ghasemi, S. Fallah, and M. Ansari, “MicroRNA-149 Is Epigenetically Silenced Tumor-suppressive microRNA, Involved in Cell Proliferation and Downregulation of AKT1 and Cyclin D1 in human Glioblastoma Multiforme,” Biochemistry and Cell Biology 94, no. 6 (2016): 569-576.

[42] T. C. Chou, “Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies,” Pharmacological Reviews 58, no. 3 (2006): 621-681.

[43] T. C. Chou, “Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method,” Cancer Research 70, no. 2 (2010): 440-446.

[44] L. Zhang, J. Feng, S. Kong, et al., “Nujiangexathone A, a Novel Compound From Garcinia nujiangensis, Suppresses Cervical Cancer Growth by Targeting hnRNPK,” Cancer Letters 380, no. 2 (2016): 447-456.

[45] B. Xin, F. Tao, Y. Wang, H. Liu, C. Ma, and P. Xu, “Coordination of Metabolic Pathways: Enhanced Carbon Conservation in 1,3-propanediol Production by Coupling With Optically Pure Lactate Biosynthesis,” Metabolic Engineering 41 (2017): 102-114.

[46] W. Wu, K. Liu, Z. You, and J. Zhang, “MiR-196b-3p and miR-450b-3p are Key Regulators of Adipogenesis in Porcine Intramuscular and Subcutaneous Adipocytes,” BMC Genomics [Electronic Resource] 24, no. 1 (2023): 360.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.